title: [Biological therapy in sympathetic ophthalmia refractory to combined immunosuppressive treatment].
authors.forename: M J
authors.initials: MJ
authors.lastname: López-Prats
authors.forename: D
authors.initials: D
authors.lastname: Salom
authors.forename: E
authors.initials: E
authors.lastname: Sanz-Marco
authors.forename: S
authors.initials: S
authors.lastname: García-Delpech
authors.forename: P
authors.initials: P
authors.lastname: Udaondo
authors.forename: M
authors.initials: M
authors.lastname: Díaz-Llopis
mesh_terms: D000068879:Adalimumab; D000328:Adult; D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use*; D001691:Biological Therapy; D003131:Combined Modality Therapy; D016572:Cyclosporine / Q000008:administration & dosage / Q000627:therapeutic use; D004351:Drug Resistance; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D007166:Immunosuppressive Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D008727:Methotrexate / Q000008:administration & dosage / Q000627:therapeutic use; D009879:Ophthalmia, Sympathetic / Q000188:drug therapy / Q000209:etiology / Q000628:therapy*; D011183:Postoperative Complications / Q000188:drug therapy / Q000209:etiology / Q000628:therapy*; D011241:Prednisone / Q000627:therapeutic use; D012163:Retinal Detachment / Q000601:surgery; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors*
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D007166:Immunosuppressive Agents; D014409:Tumor Necrosis Factor-alpha; D016572:Cyclosporine; D000068879:Adalimumab; D011241:Prednisone; D008727:Methotrexate